TY - JOUR
T1 - Complement system and the brain
T2 - Selected pathologies and avenues toward engineering of neurological nanomedicines
AU - Lettiero, Barbara
AU - Andersen, Alina J.
AU - Hunter, A. Christy
AU - Moghimi, Seyed Moein
N1 - Funding Information:
We gratefully acknowledge financial support by the European Community's Seventh framework Programme (FP7/2007–2013) under grant agreement number 212043 (NAD) and the Danish Agency for Science, Technology and Innovation reference 09-065746/DSF .
PY - 2012/7/20
Y1 - 2012/7/20
N2 - Several nanoparticle systems and supramolecular assemblies are under investigation as potential therapeutic entities for Alzheimer's disease and other neurological disorders through both brain-specific targeting and peripheral effects. However, activation of the complement system, a complex innate immune network of over 30 circulating and membrane-bound proteins, remains a serious concern related to the use of these prospective neurological nanomedicines. The role of complement in processes of neurodegeneration in the injured or aged and diseased central nervous system is well known. Nanoparticle-mediated complement activation cannot only induce adverse cardiopulmonary distress in sensitive subjects, but may further aggravate the already-compromised condition of neurological disorders and diseases. This minireview briefly examines the role of complement in neurological diseases and outlines the current status of the development of key neurological nanomedicines with respect to complement activation. Understanding of these topics is crucial for rational design and development of safe neurological nanomedicines.
AB - Several nanoparticle systems and supramolecular assemblies are under investigation as potential therapeutic entities for Alzheimer's disease and other neurological disorders through both brain-specific targeting and peripheral effects. However, activation of the complement system, a complex innate immune network of over 30 circulating and membrane-bound proteins, remains a serious concern related to the use of these prospective neurological nanomedicines. The role of complement in processes of neurodegeneration in the injured or aged and diseased central nervous system is well known. Nanoparticle-mediated complement activation cannot only induce adverse cardiopulmonary distress in sensitive subjects, but may further aggravate the already-compromised condition of neurological disorders and diseases. This minireview briefly examines the role of complement in neurological diseases and outlines the current status of the development of key neurological nanomedicines with respect to complement activation. Understanding of these topics is crucial for rational design and development of safe neurological nanomedicines.
KW - Alzheimer's disease
KW - Brain
KW - Complement: nanoparticles
KW - Liposomes
KW - Neurological nanomedicines
UR - http://www.scopus.com/inward/record.url?scp=84862687917&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862687917&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2011.10.036
DO - 10.1016/j.jconrel.2011.10.036
M3 - Review article
C2 - 22094105
AN - SCOPUS:84862687917
SN - 0168-3659
VL - 161
SP - 283
EP - 289
JO - Journal of Controlled Release
JF - Journal of Controlled Release
IS - 2
ER -